Answers are grounded in this paper and cite their sources.
Pleural mesothelioma (PM) is an aggressive malignancy with limited therapeutic options, underscoring the need for novel therapeutic alternatives. Exosomes, a subset of extracellular vesicles mediating intercellular communication, have emerged as potential therapeutic platforms due to their ability to transfer functional biomolecules and modulate cellular responses. In PM, however, exosomes exert context-dependent effects: tumor-derived exosomes actively contribute to tumor progression, immune modulation, and therapy resistance, while exosomes of non-tumor origin or those subjected to engineering approaches may be exploited for targeted therapeutic delivery. This review discusses the mechanistic foundations of exosome biology relevant to PM and current preclinical efforts to harness exosomes as carriers of nucleic acids, small molecules, and immune-modulatory agents. It further evaluates the influence of exosome cell-of-origin and the intrinsic therapeutic paradox arising from the dual biological roles of exosomes. Finally, key translational challenges, including optimization of exosome source, cargo loading efficiency and manufacturing scalability, are examined as major obstacles to clinical implementation. Addressing these challenges is essential for translating exosome-based strategies into more effective therapeutic interventions in this malignancy.
No takes yet. Share an insight, caveat, or question.
Cortes‐Dericks et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: